BCYC
Bicycle Therapeutics plc7.31
-0.02-0.27%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
507.08MP/E (TTM)
-Basic EPS (TTM)
-3.62Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Bicycle Therapeutics' Q3 2025 results show revenue dipping to $6.4 million from $8.1 million year-over-year, driven by milestone timing in partnerships, while year-to-date revenue holds steady at $18.9 million versus $18.8 million prior year. The net loss narrowed to $33.1 million from $42.6 million y/y, thanks to lower R&D spend, but gross margins slipped to 78.9% from 85.2% on mix shifts. Operating cash flow improved to ($25.4 million) from ($35.2 million), yielding free cash flow of ($26.1 million) after $0.7 million capex. Cash stood at $221.5 million with no debt, supporting pipeline runs. No non-GAAP metrics disclosed in the 10-Q. Pipeline delays pose ongoing risks.
8-K
Q3 loss widens on R&D push
Bicycle Therapeutics reported Q3 2025 net loss of $59.1 million, up from $50.8 million last year, driven by $58.4 million in R&D expenses amid zelenectide pevedotin trials. Cash stands at $648.3 million, funding operations into 2028 after a $38.2 million UK R&D credit. Dose selection for the Duravelo-2 mUC trial awaits Q1 2026 regulatory feedback. New board additions bolster oncology expertise.
8-K
Board adds oncology experts
Bicycle Therapeutics expanded its board from eight to ten directors on September 8, 2025, appointing Roger Dansey, M.D., as a Class III director through 2028 and Hervé Hoppenot as a Class I director through 2026. Dansey, with deep oncology development experience from Pfizer and Seagen, joins the Scientific and Nominating Committees; Hoppenot, ex-CEO of Incyte, bolsters the Audit and Compensation Committees. Their expertise sharpens pipeline execution amid upcoming milestones. Independent voices strengthen governance.
8-K
Q2 loss widens; costs cut 30%
Bicycle Therapeutics reported a Q2 2025 net loss of $79.0 million, up from $39.8 million last year, driven by $71.0 million in R&D expenses amid pipeline advances like the open Duravelo-4 trial for zelenectide pevedotin in NECTIN4-amplified NSCLC. Cash stands at $721.5 million, but a 30% cost realignment via workforce cuts extends runway into 2028. Board added Charles Swanton, M.D., Ph.D., effective August 12, 2025, bolstering expertise. Key updates loom in 2H 2025. Uncertainty lingers in clinical outcomes.
10-Q
Q2 FY2025 results
Bicycle Therapeutics' Q2 FY2025 10-Q filing primarily discloses governance updates rather than financial statements, limiting insight into operational performance. The company amended its 2020 Equity Incentive Plan on April 4, 2025, boosting the share reserve to 13,217,290 ordinary shares to support future awards, with an automatic annual increase of 5% of outstanding shares through 2032. It also updated its non-employee director compensation policy through June 18, 2025, offering annual cash fees up to $85,000 for the board chair and equity grants like 25,000 options plus 12,500 RSUs for new directors. An amended employment agreement for Chief Medical Officer Eric Westin, effective March 25, 2025, sets his base salary at $550,000 with a 50% target bonus. No financial metrics such as revenue or EPS are detailed in the provided exhibits. Competition in the biotech space remains a key risk from Risk Factors.
IPO
Employees
Sector
Industry
BCAB
BioAtla, Inc.
0.76-0.01
BCAX
Bicara Therapeutics Inc.
18.15-0.21
BCTX
BriaCell Therapeutics Corp.
8.70-0.28
BNTX
BioNTech SE
92.23-1.52
BOLT
Bolt Biotherapeutics, Inc.
5.45+0.06
CLRB
Cellectar Biosciences, Inc.
3.18-0.02
CNTX
Context Therapeutics Inc.
1.10-0.03
CYCN
Cyclerion Therapeutics, Inc.
1.53-0.07
NXTC
NextCure, Inc.
11.12-0.35
UNCY
Unicycive Therapeutics, Inc.
5.88+0.00